These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38880492)

  • 41. Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020.
    Peng C; Kuang L; Zhao J; Ross AE; Wang Z; Ciolino JB
    J Control Release; 2022 May; 345():625-645. PubMed ID: 35321827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Bibliometric Analysis of Research on Decellularized Matrix for Two Decades.
    Hou X; Zhang E; Mao Y; Luan J; Fu S
    Tissue Eng Part C Methods; 2023 Sep; 29(9):395-409. PubMed ID: 37276179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological therapy for pustular psoriasis: a systematic review.
    Falto-Aizpurua LA; Martin-Garcia RF; Carrasquillo OY; Nevares-Pomales OW; Sánchez-Flores X; Lorenzo-Rios D
    Int J Dermatol; 2020 Mar; 59(3):284-296. PubMed ID: 31612467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug survival of biologics in psoriasis: An Australian multicentre retrospective study.
    Ting S; Lowe P; Smith A; Fernández-Peñas P
    Australas J Dermatol; 2024 Jun; 65(4):350-357. PubMed ID: 38509804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Worldwide Bronchiolitis obliterans research: A bibliometric analysis of the published literature between 2002 and 2022.
    Cui Z; Zhou X; Luo F; Wang J; Diao J; Pan Y
    Medicine (Baltimore); 2023 Jul; 102(28):e34263. PubMed ID: 37443465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Knowledge mapping of programmed cell death in osteonecrosis of femoral head: a bibliometric analysis (2000-2022).
    Liang XZ; Li N; Chai JL; Li W; Luo D; Li G
    J Orthop Surg Res; 2023 Nov; 18(1):864. PubMed ID: 37957649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis.
    Yu C; Huang Y; Yan W; Jiang X
    Front Immunol; 2023; 14():1272080. PubMed ID: 37954610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Research hotspots and trends in biological agents for psoriasis: Visualization and bibliometric analysis.
    Long SY; Shang L; Zhao S; Shi H; He YL
    Heliyon; 2024 Jun; 10(11):e31054. PubMed ID: 38845913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Knowledge Mapping and Research Hotspots of Generalized Pustular Psoriasis: A Bibliometric Analysis from 2003 to 2023.
    Wei L; Zhang B; Wang L; Xu J; Liu A
    Clin Cosmet Investig Dermatol; 2023; 16():3629-3643. PubMed ID: 38144159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bimekizumab for the Treatment of Psoriasis.
    Freitas E; Blauvelt A; Torres T
    Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 2-decade bibliometric analysis of epigenetics of cardiovascular disease: from past to present.
    Mao Y; Zhao K; Chen N; Fu Q; Zhou Y; Kong C; Li P; Yang C
    Clin Epigenetics; 2023 Nov; 15(1):184. PubMed ID: 38007493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Global trends and current status in pheochromocytoma: a bibliometric analysis of publications in the last 20 years.
    Huang BL; Liu Q; Teng YY; Peng SQ; Liu Z; Li ML; Liang JY; Zhang Y; Wang M
    Front Endocrinol (Lausanne); 2023; 14():1167796. PubMed ID: 37680890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Knowledge mapping of neonatal electroencephalogram: A bibliometric analysis (2004-2022).
    Zhang R; Shi L; Zhang L; Lin X; Bao Y; Jiang F; Wu C; Wang J
    Brain Behav; 2024 May; 14(5):e3483. PubMed ID: 38680038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.